Loading patent…
AssigneeCell Signaling Technology, Inc.
InventorsKatherine Crosby, Bradley L. Smith, Valerie L. Goss
Estimating the term…
The invention provides novel reagents and methods for detecting BCR-ABL or c-Abl kinase activity, and/or Abl signaling pathway activation in a cell or tissue, and discloses novel biomarkers relevant to Abl-mediated disease progression and therapeutic responsiveness, and provides predictive and detection methods based on the same. Phosphorylated BCR-ABL (Tyr245) and/or c-Abl (Tyr245), BCR-ABL (Tyr735) and/or c-Abl (Tyr735), Bcr (Tyr177), CRKL (Tyr207), Gab1 (Tyr627), PYK2 (Tyr402), Tyk2 (Tyr1054/1055), SHP2 (Tyr580), ERK1/2 (Thr202/Tyr204) and MEK1/2 (Ser217/221) have now been identified as relevant biomarkers of c-Abl pathway-mediated disease, and phospho-specific antibodies to these targets are provided. Kits for carrying out the methods of the invention are also provided.
A method for detecting the activity of BCR-ABL or c-Abl kinase and/or the c-Abl signaling pathway in a cell or tissue, said method comprising the steps of:
A method for detecting the inhibition of BCR-ABL or c-Abl kinase by an inhibitor, said method comprising the steps of:
A method for identifying a patient likely to respond to a BCR-ABL kinase inhibitor for the treatment of CML or ALL, said method comprising the steps of:
The method of claim 8, further comprising the step of (d) comparing the level of phosphorylated protein determined in step(c) for said test cell or tissue with the level of phosphorylated protein in a reference sample characteristic of CML or ALL patients responsive to a BCR-ABL inhibitor.
A method for identifying one or more protein biomarker(s) of patient response or resistance to a BCR-ABL inhibitor for the treatment of CML or ALL, said method comprising the steps of:
A kit for detecting the inhibition of BCR-ABL kinase by an inhibitor, said kit comprising (a) at least one phospho-specific antibody selected from the group consisting of:
A kit for identifying a patient likely to respond to a BCR-ABL kinase inhibitor for the treatment of CML or ALL, said kit comprising (a) at least one phospho-specific antibody selected from the group consisting of:
Dependencies are inferred from the claim text.